Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Drug Registration Proposal Requires Clinical Trials For Follow-On Biologics - Sidley Austin

This article was originally published in PharmAsia News

Executive Summary

China's State Food and Drug Administration would require clinical studies for follow-on biologics under draft drug registration regulations published in March, according to comments submitted to SFDA by the Beijing office of U.S.-based law firm Sidley Austin

Related Content

Follow-On Biologics Get Their Vehicle As Senate Schedules Mark-Up For June 13



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts